Toll-like receptors in transplantation: sensing and reacting to injury  by Leventhal, Jeremy S. & Schröppel, Bernd
Toll-like receptors in transplantation: sensing and
reacting to injury
Jeremy S. Leventhal1 and Bernd Schro¨ppel1,2
1Division of Nephrology, Mount Sinai School of Medicine, New York, New York, USA and 2Recanati Miller Transplantation Institute,
Mount Sinai School of Medicine, New York, New York, USA
Toll-like receptors (TLRs) are a family of transmembrane
proteins that have a major role in pathogen-induced
inflammation and orchestrating an organism’s defense
against infection. Data are emerging that the TLRs play an
important role as a first response to tissue injury linking the
innate with the adaptive immune system. The recognition
that TLRs are expressed on nonimmune cells including renal
and liver cells, and that endogenous, cell-derived ligands
(damage-associated molecular patterns) can signal through
specific TLRs has expanded the understanding of how these
receptors impact a variety of diseases. This review focuses on
recent findings elucidating the ability of TLRs to affect
transplant outcomes. Specifically, observations
demonstrating the link between endogenous TLR ligands
and IR injury, how this can affect alloimmunity and transplant
tolerance, and therapeutic implications will be discussed.
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Toll-like receptors (TLRs) comprise a family of 13 known cell
surface and intracellular pattern recognition receptors that
recognize a universe of ligands expressed by potentially
invading pathogens.1 Binding of an immune cell–expressed
TLR to its pathogen-associated molecular pattern transmits
signals through the adaptors Toll/interleukin-1 receptor
domain–containing adaptor-inducing interferon (TRIF)
and/or myeloid differentiation primary response gene (88)
protein (MyD88, Figure 1).1 Most TLRs are expressed on the
cell surface, except TLR3 and TLR7–9, which encounter
intracellular ligands in endosomes or lysosomes.1 Down-
stream effects include inducing cytokine/chemokine release,
upregulating costimulatory molecules, enhancing antigen
processing/presentation, and guiding T-cell cytokine profile
induction, together initiating and amplifying, context-
specific protective immunity.
The recognition that (1) TLRs are expressed on non-
immune cells unlikely to come in contact with pathogens,2
(2) endogenous, cell-derived ligands (damage-associated
molecular patterns (DAMPs)) can bind to and signal through
specific TLRs,3 and (3) sterile inflammation can be modulated
by TLR signaling3 has expanded our current understanding
of how TLRs impact a variety of diseases. Herein we will
review recent progress in this field with an emphasis on how
DAMP-initiated TLR signaling impacts the pathophysiology
of transplant injury.
DAMAGE-ASSOCIATED MOLECULAR PATTERNS
DAMPs derive from intracellular and extracellular sources.
Intracellular DAMPs are endogenous, physiologically ex-
pressed molecules that are normally hidden from the
immune system and are released in response to cellular stress
and injury (high-mobility group box protein-1 (HMGB1),
heat shock protein (HSP), purines). Other DAMPs derive
from degradation products of normal extracellular matrix
components that in their native state cannot trigger TLR
signals. This category includes breakdown fragments of
fibronectin, biglycan, heparin sulfate, oligosaccharides of
hyaluronan, and hyaluronan fragments induced upon
inflammation (Table 1; for review, see Yu et al.3).
The best described DAMP, HMGB1, is a nuclear protein
that binds DNA and modulates transcription and chromatin
modeling. In addition to its intranuclear role, HMGB1 also
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functions as an extracellular signaling molecule during
inflammation.4 Crucial to the proinflammatory properties
of HMGB1 is cysteine residue 106 on box B. Oxidation of this
residue, as during apoptosis, decreases the inflammatory
capabilities of HMGB1 by altering its binding affinity with
TLR4.4
Accumulating evidence suggests that DAMPs induce
signaling via TLRs in a fashion analogous to pattern-
associated molecular patterns, resulting in release of proin-
flammatory cytokines and chemokines with subsequent
recruitment of inflammatory cells.3 The current concepts
are that most DAMPs interact with TLR2 and/or TLR4, but
promiscuous interactions to multiple TLRs have been
described, particularly for HMGB1 that can bind to TLR2,
TLR4, as well as TLR9 (see ref. 3) (Table 1). Structural analysis
and biochemical studies indicate that TLRs form hetero- or
homo-dimers (TLR1/TLR2, TLR2/TLR6, TLR3/TLR3, TLR4/
TLR4), which facilitates dimerization of the cytoplasmic Toll/
interleukin-1 receptor domain to activate intracellular signal-
ing.1 Despite these published results, conclusive evidence for
direct interactions between DAMPs and individual TLRs are
sparse and often not confirmed in vivo. Moreover, reports
of experimental inconsistencies are potentially related to the
effects of contaminating bacterial products including lipo-
polysaccharide (reviewed in Tsan and Gao5).
DAMPs/TLRs AND ISCHEMIC INJURY RELEVANT TO
TRANSPLANTATION
Transplantation involves harvesting the donor organ that is
subjected to ischemia–reperfusion (IR) injury and inflamma-
tion related to postsurgical healing, and both processes could
be influenced by TLR signals. IR injury leads to an influx of
neutrophils, T cells, and macrophages and can lead to
chronic injury.2 Accumulating evidence from animal models
and humans indicates that IR injury with or without
transplantation is modulated by TLR signals initiated by
DAMPs.2,3
IR injury induces upregulation of DAMPs
The list of specific DAMPs that have been described to be
induced or upregulated after IR includes HMGB1, hyalur-
onan, HSP, and biglycan, but current data have thus far only
mechanistically linked HMGB1 to the pathogenesis of IR
injury.6–8 Blocking HMGB1 before and after IR injury
improved tubular damage, whereas administering recombi-
nant HMGB1 exacerbated the injury.6 Importantly, neither
recombinant HMGB1 nor HMGB1 blockade had altered IR
injury in TLR4/ mice, supporting a critical role of the
HMGB1/TLR4 interaction in this process.6 HMGB1 was also
found to increase adhesion molecules in microvascular
endothelial cells isolated from kidneys of wild-type mice
but not TLR4/ mice.8
IR injury induces upregulation of TLRs
TLRs are not confined to cells of the immune system but are
also constitutively expressed within solid organs such as the
kidney, liver, and heart.2 Confocal microscopy localized TLR4
in the renal interstitium, possibly representing dendritic cells
(DCs),9 but the majority of the constitutive TLR2 and TLR4
expression is found in tubular epithelial cells and in
glomerular endothelial cells and podocytes8–12 (Table 2).
Several groups showed upregulation of tubular-expressed
TLR2 and TLR4 in conditions of IR injury.7,13 Moreover,
murine tubular epithelial cells require functional TLR2 to
produce chemokines and cytokines after experimentally
induced ischemia and stimulation with ischemic kidney
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Figure 1 | Toll-like receptor 4 (TLR4) signaling pathways. TLR4
is tightly bound to myeloid differentiation-2 (MD-2) on the cell
surface. CD14 and lipopolysaccharide (LPS)-binding protein (LBP)
also participate in the recognition of LPS by TLR4/MD-2. TLR4
signaling consists of a MyD88 (myeloid differentiation primary
response gene (88))-dependent and -independent cascade.
MyD88 and TIRAP (Toll/interleukin 1 receptor (TIR)
domain–containing adaptor protein) are adaptors for the MyD88-
dependent pathways, which mainly activate proinflammatory
cytokine production. TRIF (TIR domain–containing adaptor-
inducing interferon) and TRAM (TRIF-related adaptor molecule)
are adaptors for IRF3 (interferon regulatory factor 3) activation,
resulting in production of type I interferon (IFN). HMGB1, high-
mobility group box protein-1; HSP, heat shock protein.
Table 1 | Sterile inflammatory signals and putative TLR
sensors3
TLR Intracellular Extracellular matrix fragments
TLR2 HMGB129
Heat shock protein17
Hyaluronan32
Biglycan
TLR3 RNA
TLR4 Heat shock protein17
HMGB14,6,8,18,20,29
Biglycan
Heparan sulfate
Hyaluronan32
Fibrinogen
Fibronectin
TLR9 Mitochondrial DNA
HMGB1
Abbreviations: HMGB1, high-mobility group box protein-1; TLR, Toll-like receptor.
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homogenate.13 Using in situ hybridization and immunohis-
tology, TLR4 on the endothelia of vasa recta of the inner
stripe of the outer medulla was upregulated within 4 h after
ischemic injury.8 Of note, TLR4 was identified on proximal
tubules at 24 h, but not at 4 h, of reperfusion.8 Further work
is needed to expand our understanding of the differences in
the kinetics and magnitude of TLR expression at various
nephron sites.
TLR signaling impacts IR injury
The injury-promoting role of TLR4 in particular is evident in
most solid organs, as demonstrated by the protection of
TLR4-deficient mice after hepatic, renal cardiac, and cerebral
IR injury.3 Chimeric mice with deficiency in renal-associated
TLR2 and TLR4 had less renal damage and dysfunction when
compared with wild-type mice.7,13 Subsequent studies found
that TLR4 deficiency was more protective than the absence of
the downstream signaling molecule MyD88. Similarly, TLR2
deficiency was more protective than the deficiency of MyD88
or TRIF individually as well as in a combination.14,15 These
differing results on the relative importance of MyD88-
dependent and -independent signaling in conferring protec-
tion from IR injury may reflect an unknown ability of TLRs
to affect each other through dimerization, to signal via
uncharacterized pathways, or differences in ischemic model-
ing. It is important to note that the type and amount of
endogenous ligands released after IR injury depend on the
model used (for example, cold vs. warm ischemia, duration
of ischemia, unilateral vs. bilateral clamping) and likely have
significant effects on differential TLR signaling. It is further
possible that ligands released after IR injury might activate
other TLR-family members signaling via the MyD88-
dependent cascade that could have an anti-inflammatory
effect, abolishing the proinflammatory signal of TLR4.
When comparing single TLR2/ and TLR4/ with the
TLR2/4/, no increased protection was seen, indicating that
ligands prime TLR2 and TLR4 during IR injury.16
To discover the most effective molecular targets in these
complex signaling networks, it is critical to identify nexuses
where TLR receptors and cell survival or death pathways
intersect. Mkaddem et al.17 studied the role of TLRs in
mediating downstream activation of mitogen-activated
protein kinase pathways during IR injury. Ischemia activated
extracellular signal-regulated kinases 1 and 2 in wild-type and
TLR4/ kidneys but not in TLR2/ kidneys. Both TLR2
and TLR4 signaling activated mitogen-activated protein
kinase 8 and the apoptosis signal-regulating kinase 1/
mitogen-activated protein kinase 8 proapoptotic pathway,
which was critical for the IR-related injury.17 Because
apoptosis is an important feature of IR injury, modulating
signaling molecules downstream of TLR may present an
alternative for intervention.
TLR signaling impacts IR injury in humans
Our group extended animal data and found that TLR4
expression was upregulated in deceased-donor kidneys when
compared with living-donor kidneys. Only deceased-donor
but not living-donor kidneys showed tubular HMGB1
staining, and we demonstrated that HMBG1 signaled
through TLR4.18 We then tested the effect of the loss-of-
function TLR4 variants (Asp299Gly and Thr399Ile) that are
located within the extracellular domain of TLR4 and are
known to diminish ligand-receptor binding. Graft function
immediately after transplantation was markedly improved in
patients receiving a kidney carrying the loss-of-function
TLR4 mutations.18 Of note, the protective effect of the TLR4
mutations in the donor organ on IR injury was also seen in
clinical liver transplantation. We found that donor TLR4
contributed to sterile injury following cold preservation, and
recipient TLR4 genotype was linked with poor liver graft
survival among hepatitis C virus–infected recipients.19
Together, these observations in mice and humans support
the conclusion that endogenously released HMGB1 functions
through TLR4 as an intrinsic mechanism for accelerating
inflammation in response to IR injury (Figure 2). The exact
mechanism is unclear, but hypoxia-induced HMGB1 release
is promoted by TLR4-dependent reactive oxygen species
production, and optimal production of reactive oxygen
species and HMGB1 release require intact TLR4 signaling,
implicating a positive feedback loop.20
TLRs AND ALLOIMMUNE RESPONSE
TLR stimulation can theoretically directly and/or indirectly
affect the alloimmune response induced in a transplanted
organ. TLR-modulated IR injury enhances immunogenicity
of the graft that can amplify the alloresponse. The direct
effects of DAMP-transmitted TLR signals on recipient
immune cells can also amplify the response (Figure 3).
Evidence that TLR signaling is important in alloimmunity
derived from studies in MyD88/ mice. TLR signaling was
activated in response to a vascularized allograft, and
MyD88/ mice were protected from minor antigen
mismatched (HY) skin allograft rejection.21 The mechanisms
involved a reduced number of mature DCs in draining lymph
nodes, leading to impaired generation of anti-graft-reactive
T cells and impaired T helper type 1 immunity.21 Of note,
the absence of MyD88 alone did not delay rejection of fully
major histocompatibility complex–mismatched heterotopic
heart transplants or full-thickness skin grafts, even though
generation of T helper type 1 immunity was impaired.22
Producing a more complete TLR signaling blockade by
deletion of both signaling adaptors, MyD88 and TRIF, only
Table 2 | TLR2 and TLR4 expression in renal compartments
Renal compartment TLR Reference
Renal DCs TLR4 9
Tubular cells TLR2
TLR4
7,10,11
7,10,11,18
Endothelial cells TLR2
TLR4
10
8
Podocytes TLR4 12
Abbreviations: DC, dendritic cell; TLR, Toll-like receptor.
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modestly delayed rejection of major antigen-mismatched skin
grafts.23
Our group found that early after transplantation of
allogeneic islets, transcripts for TLR4 as well as potential
ligands were released or upregulated, although genetic
disruption of TLR4 on donor islets had no effect and TLR4
deficiency of recipients delayed only modestly major antigen-
mismatched graft rejection.24
TLR activation at the time of transplantation prevented
long-term acceptance of skin and heart allografts (induced
with pretransplant donor-specific transfusion and anti-
CD40L).25,26 The ensuing rejection was characterized by
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Figure 2 |Nonantigen-dependent injury amplifies inflammatory responses. DAMPs, such as HMGB1 and HSP, are released by
injury to the renal epithelium and microvascular endothelium and activate locally expressed sensing receptors (TLRs). The activation
of the innate immunity results in an adaptive immune response amplifying the injury. DAMP, danger-associated molecular pattern;
HMGB1, high-mobility group box protein-1; HSP, heat shock protein; TLR, Toll-like receptor.
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Figure 3 |Alloimmune pathways activated by TLR signaling. Acute injury such as oxidative stress during donor brain death and ischemia
can induce DAMPs that activate TLR-expressing mononuclear cells (MNCs). MNCs in particular serve to amplify TLR activation by production
of cytokines and growth factors. These events facilitate communication between different cell types, coordinating the recruitment and
activation of the alloimmune response. Injurious events in the allograft induce the generation of DAMPs, which may interact with and
activate innate TLR-expressing cells promoting chronic injury. APC, antigen-presenting cell; DAMP, danger-associated molecular pattern;
IR injury, ischemia–reperfusion injury; TLR, Toll-like receptor.
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both increased CD4þ /CD8þ effector cells and decreased
presence/function of FoxP3þCD4þ cells.26 The authors
suggest that TLR activation results in mature antigen-
presenting cells able to circumvent costimulation blockade
by preventing alloreactive CD8þ T-cell apoptosis.25 It is
important to note that although using specific TLR agonists
systemically in vivo might allow studying the role of innate
immunity on transplant tolerance induction, it is unclear
which cells mediate these effects and whether endogenous
DAMPs have similar effects in vivo.
Our group showed that alloimmune responses can
produce endogenous DAMPs and in combination with low-
dose immunosuppression recipient TLR4 deficiency can lead
to regulatory T cell–dependent prolonged graft survival.24 We
found that TLR2 and TLR4 activation resulted in the
inhibition of FoxP3þ regulatory T cell generation.24,27 It is
important to note that in these studies the endogenous TLR
activation was simulated using nonendogenous ligands (for
example, peptidoglycan) and it is unclear whether endogen-
ous ligands have similar effects on regulatory T cells in vivo.
Nevertheless, these data are compatible with evidence that
defective MyD88 signaling synergized with costimulatory
blockade to prolong skin allograft survival, and impaired
inflammation (interleukin-6/tumor necrosis factor-a pro-
duction by DCs) led to reduced effector T-cell proliferation
and increased regulation by regulatory T cells.28
DAMPs and graft survival
HMGB1 has been directly tied to transplant outcomes. In
experimental syngeneic islet transplants, b-cell-produced
HMGB1 was a key mediator for early transplant failure,
with improved islet graft survival after either anti-HMGB1
therapy or disruption of its TLR signaling receptors.29,30
Several studies have indicated a role of endogenous
DAMPs (for example, HMGB1) during alloimmune response
and their ability to alter alloreactive T-cell responses.24,31,32
HMGB1 can be passively released from cardiac allografts after
IR insult and secreted from DCs and macrophages that
infiltrate the allograft. Blockade of endogenous HMGB1
delayed rejection, reduced intragraft inflammation, and
impaired T helper type 1 immunity.31 Supporting the notion
that other DAMPs play a similar role to HMGB1, hyaluronan
fragments, which have the capacity to mature DCs via TLR2-
and TLR4-dependent regulation of CD40 and CD86, were
found to accumulate in murine skin grafts.32
Few studies have examined the role of TLR signaling in
acute allograft rejection in clinical transplantation. A
prospective study in 26 liver transplant recipients demon-
strated significantly different TLR4-dependent responses in
peripheral blood mononuclear cells of patients with early
rejection compared with nonrejectors. Analyzed before
transplantation, patients with subsequent rejection had
higher TLR4 expression on CD14þ peripheral blood
mononuclear cells and a greater capacity to induce tumor
necrosis factor-a and interleukin-6 after lipopolysaccharide
stimulation.33 The suggestion that excessive pretransplant
TLR4 signaling is a risk factor of acute allograft rejection
needs to be validated in larger studies.
Together, these data suggest that endogenous TLR ligands,
liberated during harvest, after reperfusion or chronic injury,
can significantly affect alloimmunity. This is clinically
important because therapeutically decreasing the amount of
IR injury (for example, DAMP release) could also have
beneficial effects on the alloimmune response.
TLRs AND CHRONIC ALLOGRAFT INJURY
Although numerous studies implicate TLRs in acute injury,
the effects of TLR activation on chronic injury are less clear.
Chronic allograft dysfunction is the major cause of organ loss
affecting the majority of kidney transplant recipients and is
characterized by arteriopathy, peritubular capillaropathy,
interstitial fibrosis, and tubular atrophy.
To determine the role of TLR in mediating chronic renal
graft dysfunction, Wang et al.34 studied the effect of
transplanting wild-type isografts or allografts into untreated
wild-type, TLR2/4/, MyD88/, or Trif/ recipients.
Allografts revealed increased expression of HMGB1, biglycan,
and HSP70 as early as 7 days and persisting up to 6 weeks
after transplantation. Moreover, the magnitude of DAMP
expression correlated with increased inflammation and
decreased renal allograft function when compared with
isografts. Renal allografts in TLR2/4/, MyD88/, and
Trif/ recipients showed significantly reduced glomerulo-
sclerosis, tubulointerstitial fibrosis, and better renal function
when compared with wild-type recipients.34 It is unclear how
relevant this model is to chronic transplant injury in humans.
The functional significance of transplanting TLR2/4/,
MyD88/, and Trif/ donor organs into wild-type
recipients on chronic changes is still unknown.
Evidence for TLR/DAMP signaling as a mediator of
chronic transplant injury in humans is only indirect and
associative. Kidney transplant recipients with chronic rejec-
tion have increased tissue and monocyte expression of TLR4
when compared with operationally tolerant patients, who
resemble healthy volunteers.35 These data suggest that
increased TLR4 signaling may be implicated in chronic
injury. Although patients with loss-of-function TLR4 muta-
tions (D299G and T399I) were more susceptible to post-
transplant infections, there was a beneficial impact on both
acute rejection and atherosclerotic events after kidney
transplantation.36 However, it is not clear whether decreased
atherosclerotic events can be interpreted as a measure of
decreased recipient immune activation. Consistent with the
data in chronic renal allograft injury, increased TLR4
expression in CD14þ monocytes was more pronounced in
chronic cardiac rejection (that is, transplant vasculopathy).37
Additionally, there is evidence that the immune stimula-
tory ability of hyaluronan seen in murine studies is clinically
relevant in lung transplant recipients with chronic
rejection (bronchiolitis obliterans syndrome). Chronically
rejecting lungs have higher hyaluronan levels than rejection-
free lungs.38
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Overall, these data suggest that chronic injury can be
caused in part by sterile inflammation generated in response
to chronic hypoxia secondary to loss of capillaries. DAMP
release may activate TLRs, thereby enhancing inflammation
and affecting tissue remodeling. More research is needed to
explore how TLR-induced inflammation contributes to
chronic injury.
CONCLUSIONS AND PERSPECTIVE
Although significant progress has been made to identify a
central role for TLRs in mediating IR injury, affecting
alloimmune response, and identifying certain endogenous
ligands (DAMPs), further work is needed to understand their
distinct roles, their relative importance, and the mechanisms
that generate an immune response during sterile inflamma-
tion. It remains to be established what the specific triggers
and activators are and if other classes of pattern recognition
receptors, including RIG-I-like receptors, Nod-like receptors,
and C-type lectin receptors, might play a role in addition to
TLRs.
A number of TLR-altering agents are currently being
tested for conditions other than transplantation. Continuing
research, such as the recent discovery of a TLR4 cysteine
residue critical for HMGB1 binding, may elucidate effective
pathways amenable to pharmacologic interventions.4 Other
alternatives include targeting TLRs downstream signaling
pathways, but it should be considered that TLR signaling is
also critical for tissue repair.2 Irrespective of the approach
used to target the TLR system, challenges remain in
identifying the timing, target cells, and duration of such
therapy before these interventions can be tested for use in
clinical transplantation.
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